In well-defined genetic entities, such as AML-bearing NPM1 or CEBPA (bi-allelic) mutations, the role of MLD has been downsized and the therapeutic strategies should not base upon it in this context [8,9,10,11,12]. This evidence concerns the gene CEBPA and acute myeloid leukemia.